New TALVEY® and Daratumumab Combination Shows Promise for Multiple Myeloma Treatment

Johnson & Johnson's Phase 3 MonumenTAL-3 study presents promising data for TALVEY® in combination with daratumumab. The findings could transform treatment strategies for relapsed or refractory multiple myeloma patients.